Author

Jenn Visich

Observed name: J. Visich

Institution: Regeneron (United States)

Observed institutions: Amgen (United States), Regeneron (United States)

OpenAlex ID: A5015907000

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

2022 · Naresh Bumma, Joshua Richter, et al. · Blood · 38

Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma.

2010 · A. Yin, J. Li, et al. · Journal of Clinical Oncology · 16

Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma

2016 · Ying Ou, Sameer Doshi, et al. · The Journal of Clinical Pharmacology · 13

Works count: 3

Citation count: 67

H-index: 3

I10-index: 3